Compare Incyte Corporation (INCY) vs Republic Services Inc. Common Stock (RSG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Republic Services Inc. Common Stock — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.01B), while Republic Services Inc. Common Stock trades at $227 (market cap $67.34B). The key difference: Republic Services Inc. Common Stock is far larger — about 3.1× Incyte Corporation's market cap, and Republic Services Inc. Common Stock pays a 1.22% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | RSG | |
|---|---|---|
Market Cap | $22.01B | $67.34B |
Volume | 2,589,484 | 955,255 |
Sector | Health | Industrials |
52-Week High | $129.93 | $232.27 |
52-Week Low | $86.17 | $197.73 |
Typical Hold Time | 33 Days | — |
Enterprise Value | $17.52B | $81.53B |
Dividend Yield | — | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $111.57, up 0.19% on the day, with a bearish technical signal but strong fundamentals. Recent earnings beats in Q1 and Q2 2026, with EPS of $1.81 and $3.09 respectively, highlight robust profitability. The company's net income margin improved to 27.71% in 2025, and revenue growth is projected to reach $5.8 billion in 2026. Key developments include FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting long-term growth beyond JAKAFI exclusivity post-2029.
The outlook for INCY is positive, driven by pipeline advancements and a $4 billion sales target for non-JAKAFI products. However, risks include reliance on JAKAFI until 2029 and competitive pressures. Analysts maintain a buy consensus with a $132.43 price target, suggesting ~19% upside. Investors should weigh strong cash flow and valuation metrics against execution risks in pipeline commercialization.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Republic Services Inc. Common Stock
Republic Services Inc. is a waste management company that provides non-hazardous solid waste collection, transfer, disposal, and recycling services across North America.
Read more on RSG →
